GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » Net Margin %

Northwest Biotherapeutics (Northwest Biotherapeutics) Net Margin % : -4,251.46% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Northwest Biotherapeutics's Net Income for the three months ended in Dec. 2023 was $-18.92 Mil. Northwest Biotherapeutics's Revenue for the three months ended in Dec. 2023 was $0.45 Mil. Therefore, Northwest Biotherapeutics's net margin for the quarter that ended in Dec. 2023 was -4,251.46%.

The historical rank and industry rank for Northwest Biotherapeutics's Net Margin % or its related term are showing as below:

NWBO' s Net Margin % Range Over the Past 10 Years
Min: -41039.58   Med: -7642.98   Max: 17823.48
Current: -3240.11


NWBO's Net Margin % is ranked worse than
83.64% of 1027 companies
in the Biotechnology industry
Industry Median: -162.84 vs NWBO: -3240.11

Northwest Biotherapeutics Net Margin % Historical Data

The historical data trend for Northwest Biotherapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics Net Margin % Chart

Northwest Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -863.57 -41,039.58 17,823.48 -6,240.76 -3,240.11

Northwest Biotherapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4,740.03 -1,210.45 -7,188.06 -4,576.35 -4,251.46

Competitive Comparison of Northwest Biotherapeutics's Net Margin %

For the Biotechnology subindustry, Northwest Biotherapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's Net Margin % falls into.



Northwest Biotherapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Northwest Biotherapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-62.599/1.932
=-3,240.11 %

Northwest Biotherapeutics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-18.919/0.445
=-4,251.46 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Northwest Biotherapeutics  (OTCPK:NWBO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Northwest Biotherapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics (Northwest Biotherapeutics) Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
Navid Malik director 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch officer: Chief Technical Officer 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton director, officer: Chief Scientific Officer 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman officer: See Remarks C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers director, 10 percent owner, officer: President and CEO 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski director C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis officer: See Remarks 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer director 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp 10 percent owner 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund 10 percent owner C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc. 10 percent owner 7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer director 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr. 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814

Northwest Biotherapeutics (Northwest Biotherapeutics) Headlines

From GuruFocus

Northwest Biotherapeutics Announces $15 Million Financing

By PRNewswire PRNewswire 11-29-2021